📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Event

13 April, 2026

Booth #212, San Diego, CA, US

Drug Discovery Chemistry 2026

Let’s meet at Booth #212

Drug Discovery Chemistry 2026

April 13–16, 2026 | San Diego, CA, USA

Drug Discovery Chemistry takes place in San Diego and brings together researchers focused on small molecule discovery. The meeting covers discovery chemistry, structural biology, screening approaches, and computational methods used across early research. Sessions span target classes, new modalities, hit identification, and design strategies that support lead discovery.

Meet the Sygnature Team

At Drug Discovery Chemistry 2026, we’ll contribute to conversations on modern small‑molecule discovery, including AI‑enabled design, targeted protein degradation, and approaches to challenging targets. Drawing on experience across medicinal chemistry, computational approaches, biology, and DMPK, we’ll share practical perspectives from integrated drug discovery programs to support clear, data‑led decisions as projects progress toward preclinical candidate selection.

If you would like to arrange a meeting with Allan Jordan, Hunter Shaw, René Coulombe or Romain Laporte, we are happy to schedule a time during the conference.

Book a Meeting

Allan Jordan – Vice President, Oncology Drug Discovery

Hunter Shaw – Associate Director, Business Development

René Coulombe – Senior Director, Protein Science & Structural Biology

Romain Laporte – Marketing & Events Manager, Business Development

Luncheon Presentation

Decisions, decisions: Faster discovery through Direct-to-Biology and beyond…
Presenter: Allan Jordan
Date and time: April 14th, 2026, 12:25pm

Poster Presentations

Poster #112: A structural platform for Molecular Glues and PROTACs discovery: SPR fragment screening and crystallography hit
validation with CRBNmidi
René Coulombe

Poster #113: LRRK2 Degrader Discovery: A High Throughput Direct-to-Biology Screening Platform
Allan Jordan

Poster #114: Through Hit Synergy and Beyond! Integrating Hit Finding and Direct-to-Biology to Shorten Time to Development Candidate
Allan Jordan

Poster #115: Why early process chemistry matters?
Romain Laporte

Additional Resources

  • STORM Therapeutics: From Lead to Pre‑Candidate Nomination in 18 Months
    This case study outlines how our teams worked alongside STORM Therapeutics to advance a complex DHX9 inhibitor program through a connected chemistry‑biology approach. A fully integrated discovery plan, rapid iteration, and diverse hit‑finding strategies supported the program’s progression from lead to pre‑candidate nomination in 18 months, ahead of typical industry timelines.

Can’t attend Drug Discovery Chemistry?
Connect with our team directly

Related Solutions

We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.

Direct-to-Biology

Embedding Direct‑to‑Biology methodologies into customer programs enables rapid, systematic expansion of SAR. This approach shortens the path to lead optimization and accelerates the delivery of candidate‑quality compounds.

Learn more
Therapeutic Areas

Therapeutic Areas

Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

Learn more
Hit Identification

Hit Identification

Delivering validated, high-quality hits through integrated technologies, strategic insight, and expert collaboration to advance your program with confidence.

Learn more
3D molecular visualization representing diverse therapeutic modalities in drug discovery, including PROTACs, molecular glues, peptides, and RNA-targeting therapies.

Modalities

Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

Learn more
DMPK

DMPK

Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.

Learn more
Chemistry

Chemistry

Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.

Learn more
Antibody Drug Conjugates

Antibody Drug Conjugates

Discover more about our wide range capabilities to support ADC projects.

Learn more
D structural models of biomolecules, representing structural biology techniques for drug design, epitope mapping, and fragment screening

Structural Biology

Gain structural insights that guide smarter drug design through cryo-EM, NMR, and X-ray crystallography supported by expert analysis and collaboration.

Learn more
3D molecular structure visualization used in computer aided drug design, representing structure-based and ligand-based approached for predictive modelling in drug discovery.

Computer Aided Drug Design

Our Computer Aided Drug Design (CADD) capabilities combine deep scientific expertise with advanced AI, machine learning, and informatics infrastructure to support smarter, faster decision-making across the drug discovery pipeline.

Learn more